Regeneron Pharmaceuticals, Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Leonard S. Schleifer M.D., Ph.D.
- Full Time Employees
- 15,106
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Old Saw Mill River Road Tarrytown NY United States of America 10591-6707
- IPO Date
- Apr 2, 1991
- CIK
- 0000872589
- Website
- regeneron.com
- Similar Companies
- Business
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Company News
Trump Says Pharmaceutical Tariffs Coming in Near Future
Trump says US pharma tariffs coming in not-too-distant future
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Explainer: Prescription drugs become a target in Trump's trade war
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO
Regeneron CEO Leonard Schleifer on tariffs: Let's make sure the Europeans pay their fair share
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation